Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes (Q33699243)

28 July 2017

title

Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes (English)

1 reference

28 July 2017

8

Izidore S Lossos

1 reference

28 July 2017

Ryan A Metcalf

1

1 reference

28 July 2017

Shuchun Zhao

2

1 reference

28 July 2017

Matthew W Anderson

3

1 reference

28 July 2017

Zhi Shun Lu

4

1 reference

28 July 2017

Ilana Galperin

5

1 reference

28 July 2017

Robert J Marinelli

6

1 reference

28 July 2017

Athena M Cherry

7

1 reference

28 July 2017

Yasodha Natkunam

9

1 reference

28 July 2017

publication date

8 January 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

23

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

420-433

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.173

28 July 2017

exact match

0 references

cites work

Cell cycle, CDKs and cancer: a changing paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

The Stanford Tissue Microarray Database

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

G1 phase progression: cycling on cue

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Regulation and function of cyclin D2 in B lymphocyte subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Cyclin D1-positive diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831151

Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression

30 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Cyclin D3 Expression in Non-Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.173

Expression of cyclin D2 and D3 in lymphoid lesions

21 January 2018

1 reference

12 December 2020

Selective usage of D-type cyclins in lymphoid malignancies

1 reference

12 December 2020

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

1 reference

12 December 2020

A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus

1 reference

12 December 2020

A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus

1 reference

12 December 2020

Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2

1 reference

12 December 2020

10.1038/MODPATHOL.2009.173

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference